Skip to main navigation Skip to search Skip to main content

Towards the concept of disease-modifier in post-stroke or vascular cognitive impairment: A consensus report

  • Régis Bordet*
  • , Ralf Ihl
  • , Amos D. Korczyn
  • , Giuseppe Lanza
  • , Jelka Jansa
  • , Robert Hoerr
  • , Alla Guekht
  • *Corresponding author for this work
  • Université de Lille
  • Heinrich Heine University Düsseldorf
  • IRCCS Oasi Maria SS. - Troina (EN)
  • University Clinical Center Ljubljana
  • Dr. Willmar Schwabe Pharmaceuticals
  • Pirogov Russian National Research Medical University

Research output: Contribution to journalArticlepeer-review

99 Scopus citations

Abstract

Background: Vascular cognitive impairment (VCI) is a complex spectrum encompassing post-stroke cognitive impairment (PSCI) and small vessel disease-related cognitive impairment. Despite the growing health, social, and economic burden of VCI, to date, no specific treatment is available, prompting the introduction of the concept of a disease modifier. Consensus and suggestions: Within this clinical spectrum, VCI and PSCI remain advancing conditions as neurodegenerative diseases with progression of both vascular and degenerative lesions accounting for cognitive decline. Disease-modifying strategies should integrate both pharmacological and non-pharmacological multimodal approaches, with pleiotropic effects targeting (1) endothelial and brain-blood barrier dysfunction; (2) neuronal death and axonal loss; (3) cerebral plasticity and compensatory mechanisms; and (4) degenerative-related protein misfolding. Moreover, pharmacological and non-pharmacological treatment in PSCI or VCI requires valid study designs clearly stating the definition of basic methodological issues, such as the instruments that should be used to measure eventual changes, the biomarker-based stratification of participants to be investigated, and statistical tests, as well as the inclusion and exclusion criteria that should be applied. Conclusion: A consensus emerged to propose the development of a disease-modifying strategy in VCI and PSCI based on pleiotropic pharmacological and non-pharmacological approaches.

Original languageEnglish
Article number107
JournalBMC Medicine
Volume15
Issue number1
DOIs
StatePublished - 24 May 2017

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Clinical trial
  • Disease-modifying therapy
  • Multimodal approach
  • Post-stroke cognitive impairment
  • Vascular cognitive impairment
  • Vascular dementia

Fingerprint

Dive into the research topics of 'Towards the concept of disease-modifier in post-stroke or vascular cognitive impairment: A consensus report'. Together they form a unique fingerprint.

Cite this